ATE197307T1 - Neuroaktive peptide - Google Patents

Neuroaktive peptide

Info

Publication number
ATE197307T1
ATE197307T1 AT97927691T AT97927691T ATE197307T1 AT E197307 T1 ATE197307 T1 AT E197307T1 AT 97927691 T AT97927691 T AT 97927691T AT 97927691 T AT97927691 T AT 97927691T AT E197307 T1 ATE197307 T1 AT E197307T1
Authority
AT
Austria
Prior art keywords
neuroactive peptides
specific identification
neuroactive
peptides
nmda
Prior art date
Application number
AT97927691T
Other languages
English (en)
Inventor
Joseph R Moskal
Hirotaka Yamamoto
Patricia A Colley
Original Assignee
Nyxis Neurotherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyxis Neurotherapies Inc filed Critical Nyxis Neurotherapies Inc
Application granted granted Critical
Publication of ATE197307T1 publication Critical patent/ATE197307T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97927691T 1996-05-17 1997-05-16 Neuroaktive peptide ATE197307T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/649,272 US5763393A (en) 1996-05-17 1996-05-17 Neuroactive peptides
PCT/US1997/008667 WO1997043306A1 (en) 1996-05-17 1997-05-16 Neuroactive peptides

Publications (1)

Publication Number Publication Date
ATE197307T1 true ATE197307T1 (de) 2000-11-15

Family

ID=24604116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927691T ATE197307T1 (de) 1996-05-17 1997-05-16 Neuroaktive peptide

Country Status (12)

Country Link
US (2) US5763393A (de)
EP (2) EP0914331B1 (de)
JP (1) JP2000501746A (de)
AT (1) ATE197307T1 (de)
AU (1) AU3209097A (de)
CA (1) CA2255659C (de)
DE (1) DE69703449T2 (de)
DK (1) DK0914331T3 (de)
ES (1) ES2153671T3 (de)
GR (1) GR3035227T3 (de)
PT (1) PT914331E (de)
WO (1) WO1997043306A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271366A1 (en) * 2000-06-22 2002-01-02 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
US20030022253A1 (en) * 2001-07-25 2003-01-30 Nyxis Neurotherapies, Inc. Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
ES2493316T3 (es) 2009-10-05 2014-09-11 Northwestern University GLYX-13 para uso en un método para tratar depresión que no responde al tratamiento
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
KR20210046843A (ko) 2011-04-27 2021-04-28 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
US8798716B1 (en) 2011-11-03 2014-08-05 Solstice Corporation Fiducial markers and related methods
US8974365B2 (en) 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
CA2898619C (en) 2013-01-22 2021-10-19 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009785A (es) 2013-01-29 2016-04-04 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015009772A (es) 2013-01-29 2016-05-31 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
WO2015164859A1 (en) 2014-04-25 2015-10-29 Naurex, Inc. Stable compositions of neuroactive peptides
US9994614B2 (en) * 2014-07-24 2018-06-12 Naurex, Inc. N-methyl-D-aspartate receptor modulators and methods of making and using same
SG10201810016XA (en) 2014-08-14 2018-12-28 Naurex Inc Methods of treating depression using nmda modulators
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (de) 2016-08-01 2023-03-22 Aptinyx Inc. Spöiro-lactam nmda rezeptor modulatoren und deren verwendung
EP3490993B1 (de) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spirolactam-nmda-modulatoren und verfahren zu deren verwendung
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
EP3490994B8 (de) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam und bis-spiro-lactam nmda rezeptor modulatoren und deren verwendung
JP2021512857A (ja) 2017-11-10 2021-05-20 ノーレックス インコーポレイテッド Ｎｍｄａ受容体アゴニストの投与方法
RU2020118505A (ru) 2017-12-05 2022-01-10 Наурекс Инк. Комбинация модуляторов nmda-рецептора (рапастинеля) для применения в комбинированной терапии (расстройства сна и цнс)
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列

Also Published As

Publication number Publication date
JP2000501746A (ja) 2000-02-15
WO1997043306A1 (en) 1997-11-20
ES2153671T3 (es) 2001-03-01
EP0914331B1 (de) 2000-11-02
DE69703449D1 (de) 2000-12-07
US6107271A (en) 2000-08-22
EP0914331A1 (de) 1999-05-12
AU3209097A (en) 1997-12-05
DK0914331T3 (da) 2001-02-12
CA2255659C (en) 2005-03-15
CA2255659A1 (en) 1997-11-20
DE69703449T2 (de) 2001-06-07
GR3035227T3 (en) 2001-04-30
US5763393A (en) 1998-06-09
EP1077217A2 (de) 2001-02-21
PT914331E (pt) 2001-04-30
EP1077217A3 (de) 2004-01-02

Similar Documents

Publication Publication Date Title
DE69703449D1 (de) Neuroaktive peptide
CY1114164T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
DE59710609D1 (de) Mittel zur Herstellung von Leder
EA200100447A1 (ru) Гибридные белки на основе бета-интерферона и их применение
BR0009206A (pt) Isolamento e análise de proteina
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
TR199700714A2 (xx) Paratiroit hormonu, analoglar�n�n sentezi i�in bir y�ntem.
EP0875567A3 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
ATE225806T1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
ATE412747T1 (de) Neues tumor-antigen-protein sart-3 und tumor- antigen-peptid davon
GB9816514D0 (en) Novel method
DE69704269T2 (de) Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
DE69938130D1 (de) Neue peptide
AU2172597A (en) Protein phosphatase-1 catalytic subunit interactions
NO20005081D0 (no) Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav
ATE390440T1 (de) Neuroaktive peptide
DE69632535D1 (de) Peptide zur detektion von hiv-1
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
DK0792291T3 (da) Protein, der påvirker KATP-kanaler
NO982227D0 (no) Urogenitalcarcinom-TPL komplekspeptider og antistoffer derav
DE69420044D1 (de) Blutregulierende peptide
NO20006091D0 (no) Humant protein C-polypeptid
DE69624570T2 (de) Anti-proliferationsprotein zur bacillusthuringiensis var.thuringiensis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee